A selective sweep in APOL1 is of particular interest because two allele variants have been implicated in differential outcomes of kidney donation between African–American donors and European–American donors, and it is a current target of research for improving outcomes of kidney donations and end-stage renal disease in African Americans (Freedman et al. 2016, 2020). This evidence concerns the gene APOL1 and stage 5 chronic kidney disease.